AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16306032 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine 200 mg twice daily
Number of subjects: 578
Study 16306032 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 578
Study 12032520 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA+ARA formula
Number of subjects: 194
Study 12032520 — intervention group
Group type: COMPARATOR
Intervention: Control (no DHA or ARA)
Number of subjects: 194
Study 12032520 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA formula
Number of subjects: 194
Study 12032520 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA or DHA+ARA
Number of subjects: 194
Study 9809131 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose LAAM (330 mg/week)
Number of subjects: 9
Study 9809131 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose LAAM (165 mg/week)
Number of subjects: 9
Study 7915916 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1 alpha at 3.0 micrograms/m2/d
Number of subjects: 40
Study 7915916 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1 alpha treatment
Number of subjects: 40
Study 2683506 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (cephalosporin)
Number of subjects: 80
Study 2683506 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 80
Study 1233219 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg orally)
Number of subjects: 7
Study 1233219 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (40 mg orally)
Number of subjects: 7
Study 1233219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31517663 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 44 U
Number of subjects: 101
Study 31517663 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 32 U
Number of subjects: 101
Study 31517663 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (both dosages)
Number of subjects: 101
Study 29428459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir‐boosted protease inhibitor (PI) monotherapy
Number of subjects: 296
Study 28284200 — intervention group
Group type: EXPERIMENTAL
Intervention: EarlyCDT®-Lung Test followed by X-ray and CT scanning
Number of subjects: 12000
Study 28284200 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice in the UK
Number of subjects: 12000
Study 28284200 — intervention group
Group type: EXPERIMENTAL
Intervention: EarlyCDT®-Lung Test
Number of subjects: 12000
Study 26698263 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin combined with trimetazidine
Number of subjects: 90
Study 26698263 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin alone (Control)
Number of subjects: 90
Study 24293762 — intervention group
Group type: EXPERIMENTAL
Intervention: NREM sleep (N3) during a post-learning nap
Number of subjects: 25
Study 24293762 — intervention group
Group type: EXPERIMENTAL
Intervention: REM sleep during a post-learning nap
Number of subjects: 25
Study 24293762 — intervention group
Group type: COMPARATOR
Intervention: Wake condition (no nap)
Number of subjects: 25
Study 24293762 — intervention group
Group type: EXPERIMENTAL
Intervention: NREM sleep (N3) in the wake condition
Number of subjects: 25
Study 21876312 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (100 mg orally for 12 days)
Number of subjects: 36
Study 21876312 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 36
Study 18180678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol fixed combination (n=23)
Number of subjects: 43
Study 18180678 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2% (n=23)
Number of subjects: 43
Study 18180678 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group, n=23)
Number of subjects: 43
Study 17003250 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking hygiene intervention
Number of subjects: 35
Study 17003250 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 14636936 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 600 microg sublingually
Number of subjects: 149
Study 14636936 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 800 microg vaginally
Number of subjects: 149
Study 10921543 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpyloric paracetamol administration
Number of subjects: 45
Study 10921543 — intervention group
Group type: COMPARATOR
Intervention: Gastric paracetamol administration
Number of subjects: 45
Study 10921543 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postpyloric or conventional gastric nutrition in group II
Number of subjects: 45
Study 10921543 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol pharmacokinetic study
Number of subjects: 45
Study 10921543 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiate dose
Number of subjects: 45
Study 8726596 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone, administered early
Number of subjects: 10000
Study 8726596 — intervention group
Group type: EXPERIMENTAL
Intervention: New pharmacologic agents (not specified)
Number of subjects: 10000
Study 1571340 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (cyclosporine, azathioprine, and prednisolone)
Number of subjects: 112
Study 1571340 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal
Number of subjects: 112
Study 1571340 — intervention group
Group type: COMPARATOR
Intervention: Double therapy (cyclosporine and azathioprine)
Number of subjects: 112
Study 2856757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovo-lacto-vegetarian (OLV) diet for 6 weeks
Number of subjects: 58
Study 2856757 — intervention group
Group type: COMPARATOR
Intervention: Usual diet maintained throughout 12 weeks
Number of subjects: 58
Study 28831616 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVST-OIC (home-based HIV self-testing with online counseling)
Number of subjects: 430
Study 28831616 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 430
Study 27090218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sardine-enriched diet (100 g of sardines 5 days a week for 6 months)
Number of subjects: 35
Study 27090218 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes standard diet (control group)
Number of subjects: 35
Study 25311218 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (IFRT)
Number of subjects: 1712
Study 25311218 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy
Number of subjects: 1712
Study 25311218 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, etoposide, cisplatin, and cytarabine (DECA)
Number of subjects: 1712
Study 25311218 — intervention group
Group type: COMPARATOR
Intervention: No DECA
Number of subjects: 1712
Study 25311218 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-positive results
Number of subjects: 1712
Study 25311218 — intervention group
Group type: COMPARATOR
Intervention: PET-negative results
Number of subjects: 1712
Study 25311218 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVE-PC chemotherapy
Number of subjects: 1712
Study 22151619 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical morphine gel
Number of subjects: 21
Study 22151619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 20494413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical sodium chondroitin sulfate (2.0% in phosphate-buffered saline)
Number of subjects: 65
Study 20494413 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 65
Study 20494413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical sodium chondroitin sulfate
Number of subjects: 65
Study 18547825 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (CBX)
Number of subjects: 30
Study 18547825 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac (ACF)
Number of subjects: 30
Study 18547825 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (CBX) and Aceclofenac (ACF)
Number of subjects: 30
Study 15647415 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 11
Study 15647415 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 11
Study 15647415 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin plus Metronidazole
Number of subjects: 11
Study 11925275 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Consent (EC) procedure
Number of subjects: 99
Study 11925275 — intervention group
Group type: COMPARATOR
Intervention: Routine Consent (RC) procedure
Number of subjects: 99
Study 11925275 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal comparison subjects with Enhanced Consent (EC)
Number of subjects: 99
Study 11925275 — intervention group
Group type: COMPARATOR
Intervention: Normal comparison subjects with Routine Consent (RC)
Number of subjects: 99
Study 10594413 — intervention group
Group type: EXPERIMENTAL
Intervention: Combitube
Number of subjects: 75
Study 10594413 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube
Number of subjects: 75
Study 10594413 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 75
Study 7560489 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 97
Study 7560489 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Resistance-Positive Expiratory Pressure (IR-PEP)
Number of subjects: 97
Study 7560489 — intervention group
Group type: COMPARATOR
Intervention: Routine chest physiotherapy alone
Number of subjects: 97
Study 2360434 — intervention group
Group type: EXPERIMENTAL
Intervention: Rydell nail (n=110)
Number of subjects: 220
Study 2360434 — intervention group
Group type: COMPARATOR
Intervention: LIH hook pins (n=110)
Number of subjects: 220
Study 2360434 — intervention group
Group type: EXPERIMENTAL
Intervention: Rydell nail (n=30, nondisplaced fractures)
Number of subjects: 220
Study 2360434 — intervention group
Group type: COMPARATOR
Intervention: LIH hook pins (n=16, nondisplaced fractures)
Number of subjects: 220
Study 2360434 — intervention group
Group type: EXPERIMENTAL
Intervention: Rydell nail (n=48, displaced fractures)
Number of subjects: 220
Study 2360434 — intervention group
Group type: COMPARATOR
Intervention: LIH hook pins (n=60, displaced fractures)
Number of subjects: 220
Study 346189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 18
Study 346189 — intervention group
Group type: COMPARATOR
Intervention: Quinacrine
Number of subjects: 18
Study 31094953 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and provider education program
Number of subjects: 207
Study 28425772 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 169
Study 28425772 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 169
Study 28425772 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab, Etanercept, Infliximab
Number of subjects: 169
Study 28425772 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAb
Number of subjects: 169
Study 26342556 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide (2-step group)
Number of subjects: 69
Study 26342556 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide (1-step group)
Number of subjects: 69
Study 24974134 — intervention group
Group type: EXPERIMENTAL
Intervention: NNS pre‐tube feeding (n=19)
Number of subjects: 59
Study 24974134 — intervention group
Group type: EXPERIMENTAL
Intervention: NNS on onset of tube feeding (n=20)
Number of subjects: 59
Study 24974134 — intervention group
Group type: COMPARATOR
Intervention: Control (n=20)
Number of subjects: 59
Study 23093481 — intervention group
Group type: EXPERIMENTAL
Intervention: Test tablet (newly formulated with synthetic paraffin)
Number of subjects: 0
Study 23093481 — intervention group
Group type: COMPARATOR
Intervention: Imdur® Long-Acting tablet 60 mg
Number of subjects: 0
Study 23093481 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tablets
Number of subjects: 0
Study 20042099 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone survey method
Number of subjects: 1700
Study 20042099 — intervention group
Group type: COMPARATOR
Intervention: Mail survey method
Number of subjects: 1700
Study 17479604 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 16
Study 17479604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15908849 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11774096 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital lactic acidosis (CLA)
Number of subjects: 35
Study 11774096 — intervention group
Group type: COMPARATOR
Intervention: Previously published cases (79 cases)
Number of subjects: 35
Study 9407394 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus tetracycline fibers
Number of subjects: 0
Study 9407394 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 0
Study 7970009 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (2 mg to a maximum of 36 mg/d; weeks 2 to 4)
Number of subjects: 220
Study 7970009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 7970009 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 220
Study 3620284 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine 2.5 mg
Number of subjects: 12
Study 3620284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipipanone 8 mg
Number of subjects: 12
Study 3620284 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of triprolidine 2.5 mg and dipipanone 8 mg
Number of subjects: 12
Study 3620284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29546325 — intervention group
Group type: EXPERIMENTAL
Intervention: Savvy Advanced psychoeducation program
Number of subjects: 100
Study 29677060 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired cerebral autoregulation during CPB
Number of subjects: 346
Study 29677060 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-severe large vessel stenosis
Number of subjects: 346
Study 29677060 — intervention group
Group type: EXPERIMENTAL
Intervention: Small vessel cerebral vascular disease
Number of subjects: 346
Study 29677060 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher average temperature during CPB
Number of subjects: 346
Study 29677060 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 346
Study 29677060 — intervention group
Group type: COMPARATOR
Intervention: Moderate-severe large cerebral arterial stenosis
Number of subjects: 346
Study 26992271 — intervention group
Group type: COMPARATOR
Intervention: Standard pain control with acetaminophen and opioids (SPC)
Number of subjects: 22
Study 26992271 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pain control plus gabapentin (SPC+G)
Number of subjects: 22
Study 23903371 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 416 (velcalcetide) 10 mg or more
Number of subjects: 28
Study 23903371 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 416 (velcalcetide)
Number of subjects: 28
Study 23903371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 22171015 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted A/H1N1 influenza vaccine
Number of subjects: 149
Study 19381692 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy sleep intervention
Number of subjects: 219
Study 19381692 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating control group
Number of subjects: 219
Study 17509744 — intervention group
Group type: EXPERIMENTAL
Intervention: EC40 varnish applied at baseline, 6, 12 and 18 months
Number of subjects: 2
Study 17509744 — intervention group
Group type: EXPERIMENTAL
Intervention: EC40 varnish applied at baseline, 3, 12 and 15 months
Number of subjects: 2
Study 17509744 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 2
Study 15695539 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metronidazole (1500 mg/day)
Number of subjects: 0
Study 15695539 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (250 mg three times/day)
Number of subjects: 0
Study 15695539 — intervention group
Group type: COMPARATOR
Intervention: Spiramycin/metronidazole combination (250 mg/1 500 000 units, three times/day)
Number of subjects: 0
Study 12457223 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasound
Number of subjects: 135
Study 12457223 — intervention group
Group type: COMPARATOR
Intervention: Operative cholangiography
Number of subjects: 135
Study 10893598 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen detected cases (121 participants)
Number of subjects: 121
Study 10893598 — intervention group
Group type: COMPARATOR
Intervention: Historical cases (72 participants)
Number of subjects: 121
Study 10893598 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen detected specimens (121 participants)
Number of subjects: 121
Study 10893598 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen detected tumors (60% of 121 participants)
Number of subjects: 121
Study 10893598 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen detected tumors (50% of 121 participants)
Number of subjects: 121
Study 10893598 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen detected tumors (121 participants)
Number of subjects: 121
Study 8938546 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum laminin
Number of subjects: 38
Study 8938546 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hyaluronan
Number of subjects: 38
Study 8938546 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated concentrations of laminin or hyaluronan
Number of subjects: 38
Study 1586710 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoxan (120 mg/kg) with total body irradiation (CYTBI)
Number of subjects: 101
Study 1586710 — intervention group
Group type: COMPARATOR
Intervention: busulfan (16 mg/kg) (BUSCY)
Number of subjects: 101
Study 3923941 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with FT-207 plus OK-432 (group A)
Number of subjects: 134
Study 3923941 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with only FT-207 (group B)
Number of subjects: 134
Study 2884859 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1 to 16 mg daily)
Number of subjects: 129
Study 2884859 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg daily)
Number of subjects: 129
Study 2884859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 2884859 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 129
Study 31813662 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based chemotherapy (epirubicin)
Number of subjects: 78
Study 30006861 — intervention group
Group type: EXPERIMENTAL
Intervention: s-DVC
Number of subjects: 226
Study 30006861 — intervention group
Group type: COMPARATOR
Intervention: d-DVC
Number of subjects: 226
Study 28493376 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 40 mg
Number of subjects: 413
Study 28493376 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 80 mg
Number of subjects: 413
Study 28493376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 26136179 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 90
Study 26136179 — intervention group
Group type: COMPARATOR
Intervention: Platelet-poor plasma (PPP) injection
Number of subjects: 90
Study 26136179 — intervention group
Group type: COMPARATOR
Intervention: No injection
Number of subjects: 90
Study 23733236 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary calcium scores (CS)
Number of subjects: 250
Study 23733236 — intervention group
Group type: COMPARATOR
Intervention: Diamond Forrester (DF) scores
Number of subjects: 250
Study 21291457 — intervention group
Group type: EXPERIMENTAL
Intervention: COPing with and CAring for Infants with Special Needs (COPCA) intervention group (n=21)
Number of subjects: 46
Study 21291457 — intervention group
Group type: COMPARATOR
Intervention: Traditional infant physiotherapy (TIP) intervention group (n=25)
Number of subjects: 46
Study 21291457 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapeutic actions
Number of subjects: 46
Study 20076880 — intervention group
Group type: EXPERIMENTAL
Intervention: 70W power
Number of subjects: 15
Study 20076880 — intervention group
Group type: COMPARATOR
Intervention: 50W power
Number of subjects: 15
Study 16805678 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD+EDTA+EMD
Number of subjects: 24
Study 16805678 — intervention group
Group type: COMPARATOR
Intervention: OFD+EMD
Number of subjects: 24
Study 15532360 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 2-Day 2 group (two retention tests administered 23 hr 50 min and 24 hr after practice)
Number of subjects: 0
Study 15532360 — intervention group
Group type: COMPARATOR
Intervention: Day 1-Control group (one retention test administered 20 min after practice)
Number of subjects: 0
Study 15532360 — intervention group
Group type: COMPARATOR
Intervention: Day 2-Control group (one retention test administered 24 hr after practice)
Number of subjects: 0
Study 15532360 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 1-Day 1 group (two retention tests administered 10 min and 20 min after practice)
Number of subjects: 0
Study 15532360 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 1-Day 2 group (two retention tests administered 10 min and 24 hr after practice)
Number of subjects: 0
Study 10936742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 0.5 mg + Oestradiol valerate 2.0 mg
Number of subjects: 5
Study 10936742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 1.0 mg + Oestradiol valerate 2.0 mg
Number of subjects: 5
Study 10936742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 2.0 mg + Oestradiol valerate 2.0 mg
Number of subjects: 5
Study 10936742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 3.0 mg + Oestradiol valerate 2.0 mg
Number of subjects: 5
Study 10936742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 4.0 mg + Oestradiol valerate 2.0 mg
Number of subjects: 5